SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending with high volatility following its earnings report, where an Adjusted EBITDA miss and concerns over profits heavily reliant on non-cash benefits are driving intense community discussion regarding accounting quality and allegations of related-party dealings.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart's robust quarterly performance is currently overshadowed by a cautious long-term profit outlook, sparking extensive community debate over its elevated valuation. Investors are actively discussing whether the conservative guidance signals broader economic pressures or is offset by the company's new share repurchase program and increased dividend.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a significant surge following the European Commission's conditional marketing authorization for its Anktiva bladder cancer immunotherapy, expanding its global reach to 33 countries and intensifying community speculation about a massive short squeeze. Investors are actively discussing the company's rapid international expansion, including recent Saudi approvals and upcoming developments hinted at by Dr. Pat, believing Anktiva's broad potential could drive substantial future growth and further pressure short positions.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is a major talking point ahead of its upcoming earnings, with the community weighing strategic tech integrations and a potential credit card rate cap against ongoing lawsuits and a significant insider share lock-up expiration.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending following its acquisition of Eucalyptus, igniting community debate between those optimistic about global expansion and a potential short squeeze, and others worried about the deal's valuation amidst ongoing regulatory and legal challenges.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending after reporting better-than-expected financial results and strong future guidance, challenging the narrative that AI will replace traditional software. This strong performance is leading many in the community to believe the stock is undervalued and fueling speculation about a potential short squeeze.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is experiencing significant market attention and community debate following its Q4 earnings; despite mixed results and a cautious Q1 outlook, the stock saw a notable surge, leading to discussions about the company's strong underlying Gross Order Volume and strategic investments versus concerns over valuation and conflicting analyst price target adjustments.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing active discussion following a strong earnings report that highlighted accelerating growth, improved underwriting, and narrowing losses, boosting confidence in its trajectory. Community excitement is also fueled by its innovative offer of a substantial insurance discount for Tesla FSD users, leading to anticipation of market expansion and a potential short squeeze.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending on the back of its strong earnings report, revealing record revenue and treasury, which is driving community optimism for significant growth amid ongoing discussions about undervaluation and market dynamics in the silver sector.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is surging after reporting strong Q4 earnings and authorizing a significant share buyback, alongside the strategic sale of its Depop marketplace to eBay for $1.2 billion. The community is actively debating whether this divestment is a smart move to refocus on its core business or a loss given the original acquisition cost, fueling conversation around the company's future direction in the evolving e-commerce landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.</li><li>The company now plans to make an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration in 2026, paving the way for its first-in-human clinical trials. &nbsp;</li></ul>NASDAQ-listed shares of Purple Biotech Ltd. (PPBT) soared 92% on Wednesday morning after the company achieved a manufacturing milestone for its experimental cancer drug IM1240.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/29/3176325/0/en/Purple-Biotech-Achieves-Manufacturing-Milestone-for-IM1240-a-Tri-Specific-Antibody-from-the-CAPTN-3-Platform.html">said</a> that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.IM1240 is a tri-specific antibody from the CAPTN-3 preclinical platform targeting the antigen 5T4, which is expressed in a variety of solid tumors and is associated with advanced disease, increased invasiveness, and poor clinical outcomes. The company now plans to make an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration in 2026, paving the way for its first-in-human clinical trials.<blockquote>“Drawing on my decades of experience in antibody manufacturing, producing a tri-specific protein such as IM1240 at high yield and purity was perceived as a significant challenge-one that I’m pleased to have successfully mastered.”&nbsp; Michael Schickler, Head of Clinical and Regulatory Affairs, Purple Biotech</blockquote><h2 class="st-heading-2">Window To Maintain Listing Standards&nbsp;</h2>Earlier this month, Purple Biotech received a letter from the Nasdaq, notifying the company that it is not in compliance with the minimum bid price requirement for continued listing on the bourse.&nbsp;The company now has until April 14, 2026, to regain compliance with the minimum bid price requirement.<h2 class="st-heading-2">What Is Retail Thinking?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PPBT">PPBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.A Stocktwits user now expects a dilution, provided the company needs money.<stembedurl>https://stocktwits.com/Stocksavior14/message/634120144</stembedurl>Another, however, believes that the stock will yield real profits in time.<stembedurl>https://stocktwits.com/McTradesPharmD_MBA/message/634121569</stembedurl>PPBT stock is down by 76% this year and by about 68% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-partners-with-walmart-to-expand-access-to-popular-weight-loss-drug/cLGZNj7R3wE">Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Purple Biotech Shares Soar 92% On Breakthrough For Experimental Cancer Drug

Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future development.

Equity

Shares of Purple Biotech closed down 3.4% on Monday and extended losses in after-hours trading as the company's latest financial results failed to impress the broader market, though retail traders showed some optimism.The company reported a net loss of $0.4 million for the fourth quarter of 2024, significantly narrowing from the $4.9 million loss in the same period a year earlier, primarily due to lower research and development (R&amp;D) expenses.&nbsp;Loss per American depository share (ADS) was $0.20 (basic) and $0.26 (diluted), compared to $3.80 per ADS in Q4 2023, and better than LSEG's mean analyst estimate of a loss of $1.80.CEO Gil Efron highlighted key 2024 milestones, including successful trials for its clinical-stage programs for its cancer therapy candidates <a href="https://stocktwits.com/news-articles/markets/equity/ppbt-stock-surges-on-cancer-drug-cm24-results/cJ9kF29Rh2">CM24</a> and NT219 and advancements in its CAPTN-3 tri-specific platform.&nbsp;The randomized Phase 2 trial for CM24 in second-line pancreatic cancer met all efficacy endpoints, and biomarker data informed a planned Phase 2b study for the second half of 2025.&nbsp;Meanwhile, NT219's dose escalation study determined a recommended Phase 2 dose, enabling a head and neck cancer trial in collaboration with the University of Colorado, expected to begin enrollment in early 2025.Retail sentiment on Stocktwits ended on a bullish note on Monday, but the score was slightly lower than a day ago.&nbsp;<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_as_of_March_10_03a40ad961.png" alt="PPBT sentiment and message volume as of March 10.png" width="1316" height="302"><figcaption>PPBT sentiment and message volume as of March 10. | source: Stocktwits</figcaption></figure>Some traders pointed to Purple Biotech's cash runway as a positive factor and speculated that institutional investors may disclose their positions in upcoming 13-F filings, given the strong stock-buying volume observed this year.&nbsp;<stembedurl>https://stocktwits.com/Smittysixty/message/607496322</stembedurl>However, skepticism also lingered. One user questioned the absence of a clear regulatory path for the company's drug candidates, arguing that cost-cutting measures were meaningless without a concrete FDA approval strategy.&nbsp;<stembedurl>https://stocktwits.com/Duediligence20/message/607503439</stembedurl>Others accused management of raising capital to "milk it for salaries."As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.&nbsp;In Q4, the company raised $2.8 million through a registered direct offering and an additional $1.5 million via an open-market sale of 298,000 ADSs at an average price of $3.50.<a href="https://stocktwits.com/symbol/PPBT">Purple Biotech's stock</a> has lost over 45% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Purple Biotech's Shrinking Losses Keep Retail Sentiment In The Green, But Other Pressures Loom

As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters.&nbsp;Our focus is on quality, liquid, growth-oriented, and under-followed companies in sectors actively drawing in capital such as AI, blockchain, biotech and consumer.&nbsp;This real-time news surveillance and targeting combined with our proprietary 5-point analysis, aids in uncovering stocks poised for powerful multi-day or multi-month moves—often long before Wall Street analysts catch on.&nbsp;Here’s what we’re keeping our eyes on:<h3>1. Purple Biotech (NASDAQ: PPBT)</h3>Background: Purple Biotech is a clinical-stage oncology company that aims to redefine cancer treatment through its innovative approaches targeting tumor immune evasion and drug resistance. Its lead product, CM24, is a first-in-class anti-CEACAM1 antibody being developed to treat pancreatic and other aggressive cancers. The oncology space, worth billions, continues to see intense investor interest, especially as companies explore biomarker-driven therapies.The News: Purple Biotech unveiled final Phase 2 results showing CM24 combined with nivolumab and chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in pancreatic cancer patients with specific biomarkers. The data revealed a 79% reduction in death risk and a 5.1-month OS improvement, particularly in biomarker-enriched patient groups.What It Means: These results not only validate CM24’s potential but also position Purple Biotech to expand its pipeline into broader cancer applications. With a planned Phase 2b trial targeting high-CEACAM1 patients, the company is tapping into precision oncology—a sector that continues to draw investor enthusiasm due to its game-changing potential.Stock Reaction: PPBT skyrocketed 151%, reflecting the market’s recognition of this major milestone in the fight against pancreatic cancer.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_23_40_AM_19763a2e26.png" alt="Screenshot 2024-12-05 at 2.23.40 AM.png">&nbsp;<hr>&nbsp;<h3>2. Stereotaxis (NYSE: STXS)</h3>Background: Stereotaxis is at the forefront of surgical robotics, specializing in robotic magnetic navigation (RMN) systems for minimally invasive endovascular interventions. Its GenesisX system aims to improve precision, safety, and efficiency in procedures, a critical innovation as the global market for robotic-assisted surgeries is projected to grow at a double-digit CAGR over the next decade.The News: The GenesisX robotic system was showcased for the first time at the RSNA 2024 Annual Meeting, in collaboration with Neusoft Medical Systems. The partnership aligns GenesisX with advanced imaging technologies, offering enhanced capabilities for healthcare providers worldwide.What It Means: The exposure at RSNA, one of the largest radiology conferences globally, strengthens Stereotaxis' visibility and positions the GenesisX as a next-generation tool for minimally invasive surgeries. This partnership could unlock new revenue streams as the healthcare sector increasingly adopts robotic solutions.Stock Reaction: STXS edged up 4.18%, with investors optimistic about the long-term implications of the GenesisX system.Stocktwits.com Sentiment &amp; Popularity:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_25_09_AM_6fecf5b145.png" alt="Screenshot 2024-12-05 at 2.25.09 AM.png">&nbsp;<hr>&nbsp;<h3>3. Delcath Systems (NASDAQ: DCTH)</h3>Background: Delcath Systems focuses on innovative therapies for primary and metastatic liver cancers. Its flagship product, HEPZATO KIT™, offers a unique approach to delivering high-dose chemotherapy directly to the liver while minimizing systemic exposure. This precision is critical for targeting liver-dominant diseases—a market that represents tens of thousands of patients annually.The News: The FDA has cleared Delcath’s Phase 2 trial of HEPZATO in liver-dominant metastatic colorectal cancer. The study will compare HEPZATO plus standard chemotherapy with chemotherapy alone, aiming to validate its safety and efficacy in this high-need population.What It Means: HEPZATO has already shown promise in metastatic uveal melanoma, and this expansion could significantly broaden its market reach. The ability to address liver-dominant cancers positions Delcath as a potential leader in a niche but high-value market.Stock Reaction: DCTH rose 6.4% on the day, continuing its strong performance following a 203% year-to-date rally.&nbsp;&nbsp;<hr>&nbsp;<h3>4. BrainStorm Cell Therapeutics (NASDAQ: BCLI)</h3>Background: BrainStorm is a pioneering biotech company developing autologous adult stem cell therapies for neurodegenerative diseases like ALS and progressive MS. Its lead candidate, NurOwn®, is designed to deliver neurotrophic factors directly to damaged neurons, potentially altering the course of these debilitating diseases. With few effective therapies for ALS, the market is ripe for disruptive innovation.The News: BrainStorm announced a December 11 webinar featuring updates on its Phase 3b trial of NurOwn, aimed at refining the therapy’s efficacy for FDA approval. This comes as the company prepares for a pivotal registrational trial.What It Means: If successful, NurOwn could be the first significant breakthrough for ALS in years, addressing an unmet medical need in a multibillion-dollar market. The company’s focus on early-stage ALS patients may improve trial outcomes and strengthen its case for regulatory approval.Stock Reaction: BCLI dipped 2.66%, reflecting cautious investor sentiment as the market awaits trial data.Stocktwits.com Sentiment &amp; Popularity:<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_26_15_AM_28681ca8de.png" alt="Screenshot 2024-12-05 at 2.26.15 AM.png">&nbsp;<hr>&nbsp;<h3>5. DMG Blockchain Solutions (OTCQB: DMGGF)</h3>Background: DMG Blockchain integrates Bitcoin mining with sustainability and AI-driven data centers. Its Terra Pool initiative is designed to create a carbon-neutral Bitcoin mining ecosystem, catering to ESG-conscious investors and industries. With institutional adoption of Bitcoin accelerating, DMG’s dual focus on growth and environmental responsibility makes it a standout.The News: DMG reported November mining results of 32 BTC, an increased hashrate of 1.66 EH/s, and significant insider purchases by its CEO and COO. The company also secured $17.3 million to fund growth initiatives, including AI and blockchain infrastructure.What It Means: The raised capital and insider purchases signal confidence in DMG’s ability to scale operations and align with Bitcoin’s anticipated market growth. The focus on sustainability could attract institutional players prioritizing ESG compliance.Stock Reaction: DMGI remained stable dipping just slightly, with the market digesting the long-term growth potential from recent investments.&nbsp;<hr>&nbsp;<h3>6. BriaCell Therapeutics (NASDAQ: BCTX)</h3>Background: BriaCell specializes in novel immunotherapies targeting advanced breast cancer. Its lead therapy, Bria-IMT™, is designed to boost the immune system's response against tumors. With metastatic breast cancer affecting over 2 million women globally, there’s an urgent need for effective treatments.The News: BriaCell’s pivotal Phase 3 study of Bria-IMT received a positive safety review from the DSMB, allowing the trial to proceed without changes. The trial is being conducted under the FDA’s Fast Track Designation.What It Means: The DSMB’s approval reinforces Bria-IMT’s safety and paves the way for the company to potentially deliver a game-changing therapy for metastatic breast cancer patients. The Fast Track Designation further emphasizes its potential impact.Stock Reaction: BCTX shares soared 13%, reflecting growing investor confidence in the company’s clinical progress.Rumours from Twitter:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_2_27_31_AM_e685b0a306.png" alt="Screenshot 2024-12-05 at 2.27.31 AM.png">&nbsp;&nbsp;<h3>7. Laser Photonics Corporation (NASDAQ: LASE)</h3>Background: Laser Photonics Corporation specializes in industrial laser systems, providing innovative solutions for cleaning, material processing, and now pharmaceuticals. With its recent acquisition of Control Micro Systems, Inc., the company is expanding into new sectors, including the fast-growing pharmaceutical and semiconductor industries. The industrial laser market, driven by advances in automation and precision engineering, is projected to exceed $10 billion by 2030, making it a hotbed for innovation.The News: Laser Photonics announced the successful installation of a state-of-the-art pill drilling system at a customer’s facility. The system, a Class I automated CO2 laser with advanced fume extraction and machine vision inspection, is designed to streamline pill production processes. This system also doubles as an anti-counterfeiting solution, addressing critical challenges in the pharmaceutical supply chain.What It Means: This installation signifies Laser Photonics’ pivot into high-demand verticals like pharmaceuticals. By integrating advanced laser technology with automated inspection, the company is positioning itself as a key supplier in a market prioritizing efficiency, precision, and security.Stock Reaction: LASE shares declined 6.40%, reflecting broader market volatility rather than company-specific concerns. Investors appear cautiously optimistic about the company's potential in its newly targeted markets.&nbsp;Also Read:<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/featured/why-this-small-biotech-stock-could-be-primed-for-a-breakout/">&nbsp;Why This Small Biotech Stock Could Be Primed for a Breakout</a>Be the First to Know:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/newsletter-sign-up/">Our email list eats first! Get exclusive alerts on explosive stock picks like&nbsp;AST SpaceMobile (NASDAQ: ASTS), which shot up&nbsp;+533% after our profile. Get our email signals based on our proprietary 5-indicator system before any of our other platforms by clicking here.</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

<a href="https://stocktwits.com/symbol/PPBT">Shares of Purple Biotech</a> (PPBT) surged more than 45% on Monday morning, reaching their highest levels since early October.&nbsp;The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma (PDAC).“We are very excited about the final data, demonstrating CM24’s clear and consistent improvement across all efficacy endpoints evaluated in our randomized Phase 2 study,” stated Purple Biotech CEO Gil Efron.&nbsp;He added that the enhanced results in patients with CEACAM1 and other serum markers gave them optimism that selecting a biomarker-enriched patient population could further increase CM24’s efficacy, potentially positioning it as a treatment for multiple CEACAM1-expressing malignancies.The Phase 2 study evaluated CM24, a novel first-in-class anti-CEACAM1 antibody, in combination with Bristol Myers Squibb’s immune checkpoint inhibitor nivolumab and standard-of-care chemotherapy in second-line metastatic PDAC patients. This was compared to chemotherapy alone.<figure class="image"><a href="https://stocktwits.com/symbol/PPBT"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/PPBT_sentiment_and_message_volume_9a32199173.png" alt="PPBT sentiment and message volume.png" width="1314" height="320"></a><figcaption>PPBT sentiment and message volume on Dec 2 as of 10:00 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for PPBT soared to an ‘extremely bullish’ (93/100) score, up from ‘neutral’ just a day ago, accompanied by a surge in message volume.&nbsp;One user optimistically said that PPBT should be trading at $250 per share, 50 times its current price, while another referred to CM24 as “the only pancreatic cancer drug.”<stembedurl>https://stocktwits.com/Duediligence20/message/594680510</stembedurl><stembedurl>https://stocktwits.com/Jpurpleteam/message/594672273</stembedurl>CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.&nbsp;The drug also affects serum neutrophil extracellular trap (NET) levels, which are involved in trapping and neutralizing pathogens.Still, PPBT stock has dropped more than 65% year-to-date.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nio-li-xpev-stocks-in-focus-after-record-november/cJ9kNexRhT">Nio, Li Auto, Xpeng Stocks In Focus After China EV Makers Set Monthly Record Deliveries In November</a>

The Israel-based biopharma reported positive final results from a randomized Phase 2 study of its lead oncology drug, CM24, in patients with pancreatic ductal adenocarcinoma.

Purple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail Thrilled

CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.

Purple Biotech Ltd. is a clinical-stage company, which engages in developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The oncology pipeline includes CM24, NT219, and CAPTN-3. The CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and survival through multiple pathways. The NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. The CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells and NK cells to induce a strong, localized immune response within the tumor microenvironment. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

Purple Biotech Ltd - ADR

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

PPBT
Purple Biotech Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest PPBT News

PPBTPurple Biotech Ltd - ADR